SEC Form 15-12G filed by ObsEva SA

$OBSV
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $OBSV alert in real time by email
15-12G 1 d501337d1512g.htm 15-12G 15-12G

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 15

 

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number: 001-37993

 

 

OBSEVA SA

(Exact name of registrant as specified in its charter)

 

 

Chemin des Aulx, 12, Plan-les-Ouates, 1228, Geneva Switzerland

+ 41 22 552 38 40

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Common shares, par value CHF 1/13 per share

(Title of each class of securities covered by this Form)

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1)

 

Rule 12g-4(a)(2)

 

Rule 12h-3(b)(1)(i)

 

Rule 12h-3(b)(1)(ii)

 

Rule 15d-6

 

Rule 15d-22(b)

 

Approximate number of holders of record as of the certification or notice date:

Common shares, par value CHF 1/13 per share – 104

Pursuant to the requirements of the Securities Exchange Act of 1934, ObsEva SA has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

Date: April 26, 2023

   

By:

 

/s/ Will Brown

   

Name:

 

Will Brown

   

Title:

 

Interim Chief Executive Officer and Chief

Financial Officer

 

 

 

Get the next $OBSV alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$OBSV

DatePrice TargetRatingAnalyst
8/30/2022Buy → Neutral
H.C. Wainwright
6/3/2022$6.00Overweight
Cantor Fitzgerald
4/26/2022$12.00Buy
Canaccord Genuity
3/28/2022$12.00Buy
Aegis Capital
11/29/2021$17.00 → $15.00Buy
HC Wainwright & Co.
More analyst ratings

$OBSV
Press Releases

Fastest customizable press release news feed in the world

See more
  • ObsEva Files Year End 2022 Financial Statements

    ObsEva Files Year End 2022 Financial Statements Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 31, 2023 – ObsEva SA (SIX: OBSN / OTC Pink Market: OBSVF), a biopharmaceutical company developing and commercializing novel therapies to improve women's health, today published its U.S. Annual Report on Form 10-K for Fiscal Year 2022, including the U.S. GAAP financial results for year-end 2022. The U.S. Annual Report on Form 10-K can be accessed in the financial section of the Company's website, here or directly via the link here. ObsEva expects to publish its Swiss Annual Report to Shareholders, including the financial results for year end 20

    $OBSV
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • ObsEva Announces Progress Towards its Plans to Consolidate Operations in Switzerland: Delisting of OBSV from The Nasdaq Stock Market effective March 23, 2023

    Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 15, 2023 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that it received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq") on March 14, 2023, advising the Company that its securities are scheduled for delisting from The Nasdaq Capital Market and will be suspended at the opening of U.S. business on March 23, 2023. A Form 25-NSE will be filed with the Securities and Exchange Commission (the "SEC"), which will remove the Company's securities from listing and registration on Nasd

    $OBSV
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • ObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in Switzerland

    Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 13, 2023 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that Ernest Loumaye, MD, PhD, co-founder and member of the Board of Directors has been appointed as Interim Chairman following the resignation of Annette Clancy. It is expected that Dr. Loumaye will serve in this position until the 2023 Annual General Meeting of Shareholders, at which time he will be nominated for this position for the upcoming year. Additionally, the Company announced the appointment of Fabien de Ladonchamps as Chief

    $OBSV
    Biotechnology: Pharmaceutical Preparations
    Health Care

$OBSV
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$OBSV
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$OBSV
SEC Filings

See more

$OBSV
Leadership Updates

Live Leadership Updates

See more
  • ObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in Switzerland

    Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 13, 2023 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that Ernest Loumaye, MD, PhD, co-founder and member of the Board of Directors has been appointed as Interim Chairman following the resignation of Annette Clancy. It is expected that Dr. Loumaye will serve in this position until the 2023 Annual General Meeting of Shareholders, at which time he will be nominated for this position for the upcoming year. Additionally, the Company announced the appointment of Fabien de Ladonchamps as Chief

    $OBSV
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • ObsEva Announces Appointment of Annette Clancy as Chair of the Board of Directors

    GENEVA, Switzerland May 19, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced the appointment of Annette Clancy as Chair of the Board of Directors at the Company's Annual General Meeting on May 18, 2022. Ms. Clancy has served as a member of ObsEva's Board of Directors since 2013 and was previously Chair from November 2013 to December 2016. Ms. Clancy succeeds Dr. Frank Verwiel, who had decided to step down from the role of Chair and retire from the Board of Directors, effective following the conclusion of the Annual General Meeting. "We could not be more pleased, or fortunate, to have

    $OBSV
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer

    Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – May 2, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced the appointment of Dr. Brandi Howard as Chief Clinical Officer and member of the company's Executive Committee, effective May 9, 2022. Dr. Howard, who brings to ObsEva more than 20 years of women's health expertise, will be responsible for the Company's clinical development and medical affairs strategy. She succeeds Dr. Elizabeth Garner, who will be departing the Company on May 6, 2022 to pursue a new opportunity. To help ensure a smooth tra

    $EVFM
    $OBSV
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$OBSV
Financials

Live finance-specific insights

See more
  • ObsEva Announces First Quarter 2022 Financial Results and Provides Corporate Update

    -Linzagolix for uterine fibroids: Received confirmation of positive CHMP opinion for marketing authorization application; United States NDA PDUFA date in Q3:22- -Linzagolix for endometriosis: Reported positive topline results for linzagolix 200 mg with add-back therapy in the Phase 3 EDELWEISS 3 trial- -Linzagolix franchise: Announced licensing agreement with Theramex to support commercialization in Europe, in addition to relationship with Syneos Health to support commercialization in the United States- Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange                 GENEVA, Switzerland – May 17, 2022 – ObsEva SA (NASDAQ:OBSV) (SIX: OBSN), a biopharma

    $OBSV
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • ObsEva to Host Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Business Update

    GENEVA, Switzerland – May 12, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that it plans to host a conference call on Tuesday, May 17, 2022, at 8:00 a.m. ET to discuss its financial results for the quarter ended March 31, 2022 and provide a business update. Individuals may participate via telephone by dialling (877) 300-8521 (domestic) or +1 (412) 317-6026 (international) and using conference ID 10166576. The webcast can be accessed live here and will also be accessible under "Events Calendar" in the investors section of ObsEva's website. The webcast will be archived on the company

    $OBSV
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain

    -Once daily linzagolix 200 mg with ABT met both co-primary efficacy objectives, demonstrating reductions in dysmenorrhea and non-menstrual pelvic pain versus placebo at 3 months; showed statistically significant and clinically meaningful improvements versus placebo in ranked secondary endpoints of dysmenorrhea, non-menstrual pelvic pain, dyschezia, overall pelvic pain, and ability to perform daily activities at 6 months- -Once daily linzagolix 75 mg without ABT demonstrated statistically significant improvement for dysmenorrhea versus placebo and showed improvement but did not meet the co-primary objective of reduction in non-menstrual pelvic pain at 3 months; also showed improvement in sec

    $OBSV
    Biotechnology: Pharmaceutical Preparations
    Health Care

$OBSV
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more